Biocon and Mylan have received European Medicines Agency’s (EMA) acceptance to review Mylan’s marketing authorisation application (MAA) for a proposed biosimilar Trastuzumab used to treat certain HER2-positive breast and gastric cancers. This is the second biosimilar submission developed by the partnership that has been accepted for review in Europe. In July, Mylan’s MAA for the proposed biosimilar Pegfilgrastim was accepted for review by EMA.
ICICI Securities Limited have introduced FY19 estimates (both for Biocon and Syngene) on account of better visibility and proven capability. SOTP target price is now | 1030.